Gerard P Zambetti

List of Publications by Year
in descending order

124	14,526	29994 54	22764 112
papers	citations	h-index	g-index

128	128	128	16520
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical and Functional Significance of TP53 Exon 4â€“Intron 4 Splice Junction Variants. Molecular Cancer Research, 2022, 20, 207-216.	1.5	4
2	TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC. Cancers, 2022, 14, 1655.	1.7	3
3	Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers. Cancers, 2022, 14, 3014.	1.7	1
4	The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Research, 2021, 81, 2442-2456.	0.4	9
5	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal of Clinical Oncology, 2021, 39, 2463-2473.	0.8	38
6	Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. Frontiers in Endocrinology, 2021, 12, 756523.	1.5	2
7	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
8	What 20 years of research has taught us about the TP53 p.R337H mutation. Cancer, 2020, 126, 4678-4686.	2.0	30
9	A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. British Journal of Cancer, 2020, 122, 1231-1241.	2.9	8
10	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	4.7	37
11	Pediatric adrenocortical tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101448.	2.2	29
12	Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. Cancers, 2020, 12, 506.	1.7	17
13	Arnie Levine and the MDM2â€“p53 discovery: a postdoctoral fellowâ€™s perspective. Journal of Molecular Cell Biology, 2019, 11, 620-623.	1.5	0
14	From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. Journal of Physical Education and Sports Management, 2019, 5, a003921.	0.5	4
15	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nature Communications, 2019, 10, 5806.	5.8	27
16	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. JCO Precision Oncology, 2019, 3, 1-21.	1.5	6
17	Spatial trends in congenital malformations and stream water chemistry in Southern Brazil. Science of the Total Environment, 2019, 650, 1278-1291.	3.9	11
18	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. Journal of the Endocrine Society, 2019, 3, .	0.1	0

#	Article	IF	Citations
19	SAT-LB058 Effect of a Genetic Modifier of Cancer Risk in TP53 Mutation Carriers. Journal of the Endocrine Society, 2019, 3, .	0.1	0
20	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. Acta Neuropathologica, 2018, 136, 315-326.	3.9	26
21	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	0.8	121
22	KDM5A Regulates a Translational Program that Controls p53 Protein Expression. IScience, 2018, 9, 84-100.	1.9	25
23	Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Childrenâ€™s Oncology Group Study. Journal of Clinical Oncology, 2017, 35, 3956-3963.	0.8	33
24	The Inherited p53 Mutation in the Brazilian Population. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026195.	2.9	60
25	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Endocrine-Related Cancer, 2016, 23, 825-837.	1.6	17
26	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. Clinical Cancer Research, 2016, 22, 6247-6255.	3.2	22
27	IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma. Molecular and Cellular Endocrinology, 2016, 428, 82-88.	1.6	11
28	Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Childrenâ€™s Oncology Group ARAR0332 protocol.. Journal of Clinical Oncology, 2016, 34, 10515-10515.	0.8	12
29	Prevalence and Functional Consequence of TP53 Mutations in Pediatric Adrenocortical Carcinoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 602-609.	0.8	164
30	Genomic landscape of paediatric adrenocortical tumours. Nature Communications, 2015, 6, 6302.	5.8	166
31	Abstract A52: Paracrine apoptotic effect of the tumor suppressor p53 is mediated by secreted Par-4. , 2015, , .		0
32	The p53-induced factor Ei24 inhibits nuclear import through an importin Î²â€“bindingâ€“like domain. Journal of Cell Biology, 2014, 205, 301-312.	2.3	28
33	p53/TAp63 and AKT Regulate Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling through Two Independent Parallel Pathways in the Presence of DNA Damage. Journal of Biological Chemistry, 2014, 289, 4083-4094.	1.6	50
34	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nature Communications, 2014, 5, 3630.	5.8	342
35	Paracrine Apoptotic Effect of p53 Mediated by Tumor Suppressor Par-4. Cell Reports, 2014, 6, 271-277.	2.9	33
36	Childhood Adrenocortical Carcinoma. , 2014, , 962-967.		0

#	Article	IF	Citations
37	PUMA and BIM Are Required for Oncogene Inactivationâ€“Induced Apoptosis. Science Signaling, 2013, 6, ra20.	1.6	107
38	Impact of Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. Journal of Clinical Oncology, 2013, 31, 2619-2626.	0.8	156
39	Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent. Clinical Cancer Research, 2013, 19, 1740-1747.	3.2	29
40	MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma. Journal of Biological Chemistry, 2013, 288, 21307-21319.	1.6	95
41	SNP Array Profiling of Childhood Adrenocortical Tumors Reveals Distinct Pathways of Tumorigenesis and Highlights Candidate Driver Genes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1284-E1293.	1.8	41
42	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood, 2012, 120, 3764-3773.	0.6	132
43	Assessing telomeric DNA content in pediatric cancers using whole-genome sequencing data. Genome Biology, 2012, 13, R113.	13.9	31
44	Context-Dependent Enhancement of Induced Pluripotent Stem Cell Reprogramming by Silencing Puma. Stem Cells, 2012, 30, 888-897.	1.4	24
45	Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Molecular and Cellular Endocrinology, 2012, 351, 101-110.	1.6	65
46	The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Molecular and Cellular Endocrinology, 2012, 351, 37-43.	1.6	103
47	Abstract 1353: Inactivation of ribosomal protein L22 promotes transformation by induction of Lin28B. , 2012, , .		0
48	Akt Requires Glucose Metabolism to Suppress Puma Expression and Prevent Apoptosis of Leukemic T Cells. Journal of Biological Chemistry, 2011, 286, 5921-5933.	1.6	94
49	Genetics and genomics of childhood adrenocortical tumors. Molecular and Cellular Endocrinology, 2011, 336, 169-173.	1.6	17
50	Placental Alkaline Phosphatase in Pediatric Adrenocortical Cancer. Journal of Pediatric Hematology/Oncology, 2011, 33, e149-e153.	0.3	11
51	The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle, 2011, 10, 2380-2389.	1.3	59
52	Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor. Familial Cancer, 2011, 10, 141-146.	0.9	13
53	6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. Molecular Neurodegeneration, 2011, 6, 2.	4.4	69
54	TP53-Associated Pediatric Malignancies. Genes and Cancer, 2011, 2, 485-490.	0.6	30

#	Article	IF	Citations
55	Diving into in vivo p53 tumor suppressor studies using a new platform mouse model. Cell Cycle, 2011, 10, 2619-2619.	1.3	1
56	Developmental Arrest of T Cells in Rpl22-Deficient Mice Is Dependent upon Multiple p53 Effectors. Journal of Immunology, 2011, 187, 664-675.	0.4	32
57	Double null cells reveal that CBP and p300 are dispensable for p53 targetsp21andMdm2but variably required for target genes of other signaling pathways. Cell Cycle, 2011, 10, 212-221.	1.3	34
58	Identification of a Novel <emph type="ital">TP53</emph> Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML. JAMA - Journal of the American Medical Association, 2011, 305, 1568.	3.8	146
59	Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose Î³-irradiation. Blood, 2010, 115, 3472-3480.	0.6	125
60	Puma is required for p53-induced depletion of adult stem cells. Nature Cell Biology, 2010, 12, 993-998.	4.6	101
61	Regulation of Insulin-like Growth Factorâ€“Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors. Cancer Research, 2010, 70, 4666-4675.	0.4	191
62	BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program. Science, 2010, 330, 1390-1393.	6.0	416
63	The p53-Target Gene Puma Drives Neutrophil-Mediated Protection against Lethal Bacterial Sepsis. PLoS Pathogens, 2010, 6, e1001240.	2.1	23
64	Familial predisposition to adrenocortical tumors: Clinical and biological features and management strategies. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 477-490.	2.2	30
65	Adrenocortical Cancer in Children. , 2009, , 467-481.		0
66	JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis. Journal of Biological Chemistry, 2009, 284, 26591-26602.	1.6	174
67	Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-xL. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2429-2434.	1.0	0
68	Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis. Molecular Cell, 2009, 36, 487-499.	4.5	505
69	TP53 Molecular Genetics. , 2009, , 193-205.		0
70	Assays to Measure p53-Dependent and -Independent Apoptosis. Methods in Molecular Biology, 2009, 559, 143-159.	0.4	12
71	Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood, 2009, 113, 2805-2815.	0.6	108
72	Association of the germline TP53R337H mutation with breast cancer in southern Brazil. BMC Cancer, 2008, 8, 357.	1.1	65

#	Article	IF	Citations
73	High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. Cancer Genetics and Cytogenetics, 2008, 186, 19-24.	1.0	27
74	PUMA Regulates Intestinal Progenitor Cell Radiosensitivity and Gastrointestinal Syndrome. Cell Stem Cell, 2008, 2, 576-583.	5.2	199
75	Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis. Molecular and Cellular Biology, 2008, 28, 5391-5402.	1.1	130
76	Gene Expression Profiling of Childhood Adrenocortical Tumors. Cancer Research, 2007, 67, 600-608.	0.4	146
77	Increased Steroidogenic Factor-1 Dosage Triggers Adrenocortical Cell Proliferation and Cancer. Molecular Endocrinology, 2007, 21, 2968-2987.	3.7	194
78	Nephroblastoma Overexpressed/Cysteine-Rich Protein 61/Connective Tissue Growth Factor/Nephroblastoma Overexpressed Gene-3 (NOV/CCN3), a Selective Adrenocortical Cell Proapoptotic Factor, Is Down-Regulated in Childhood Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3253-3260.	1.8	52
79	Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children. Journal of Clinical Oncology, 2007, 25, 682-689.	0.8	200
80	p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion. Gut, 2007, 56, 645-654.	6.1	89
81	Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndrome. Cancer Letters, 2007, 247, 353-355.	3.2	11
82	The p53 mutation â€œgradient effectâ€•and its clinical implications. Journal of Cellular Physiology, 2007, 213, 370-373.	2.0	67
83	SF-1 overexpression in childhood adrenocortical tumours. European Journal of Cancer, 2006, 42, 1040-1043.	1.3	90
84	Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nature Cell Biology, 2006, 8, 1348-1358.	4.6	770
85	Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H52-H60.	1.5	125
86	Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development. Journal of Cell Biology, 2006, 172, 795-797.	2.3	34
87	Identification of a Novel Germ Line Variant Hotspot Mutant p53-R175L in Pediatric Adrenal Cortical Carcinoma. Cancer Research, 2006, 66, 5056-5062.	0.4	31
88	Gankyrin: An intriguing name for a novel regulator of p53 and RB. Cancer Cell, 2005, 8, 3-4.	7.7	50
89	What have animal models taught us about the p53 pathway?. Journal of Pathology, 2005, 205, 206-220.	2.1	69
90	Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatric Blood and Cancer, 2005, 45, 265-273.	0.8	127

#	Article	IF	Citations
91	Amplification of the Steroidogenic Factor 1 Gene in Childhood Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 615-619.	1.8	120
92	A New Family of Small Molecules To Probe the Reactivation of Mutant p53. Journal of the American Chemical Society, 2005, 127, 6152-6153.	6.6	67
93	Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma. Cell, 2005, 123, 641-653.	13.5	364
94	p53 Tumor-Suppressor Genes. , 2004, , 635-666.		2
95	Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell, 2003, 4, 321-328.	7.7	818
96	Reversible Amyloid Formation by the p53 Tetramerization Domain and a Cancer-associated Mutant. Journal of Molecular Biology, 2003, 327, 699-709.	2.0	72
97	Parc-ing p53 in the Cytoplasm. Cell, 2003, 112, 1-2.	13.5	32
98	A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Structural Biology, 2002, 9, 12-16.	9.7	251
99	The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene, 2001, 277, 15-30.	1.0	207
100	Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood, 2001, 98, 2084-2090.	0.6	43
101	Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo. Oncogene, 2001, 20, 303-313.	2.6	17
102	E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene, 2001, 20, 910-920.	2.6	38
103	Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene, 2001, 20, 6983-6993.	2.6	138
104	Jak3 Selectively Regulates Bax and Bcl-2 Expression To Promote T-Cell Development. Molecular and Cellular Biology, 2001, 21, 678-689.	1.1	61
105	Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1. Journal of Biological Chemistry, 2001, 276, 39359-39367.	1.6	202
106	p53 Binds Selectively to the 5â€² Untranslated Region of cdk4 , an RNA Element Necessary and Sufficient for Transforming Growth Factor Î²- and p53-Mediated Translational Inhibition of cdk4. Molecular and Cellular Biology, 2000, 20, 8420-8431.	1.1	71
107	ei24, a p53 Response Gene Involved in Growth Suppression and Apoptosis. Molecular and Cellular Biology, 2000, 20, 233-241.	1.1	119
108	p53-independent functions of the p19ARF tumor suppressor. Genes and Development, 2000, 14, 2358-2365.	2.7	317

#	Article	IF	Citations
109	Sp1 and Egr-1 Have Opposing Effects on the Regulation of the RatPgp2/mdr1b Gene. Journal of Biological Chemistry, 1999, 274, 3199-3206.	1.6	54
110	Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. FEBS Journal, 1998, 256, 510-517.	0.2	31
111	Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain. Molecular and Cellular Biology, 1998, 18, 3735-3743.	1.1	188
112	Regulators and mediators of the p53 tumor suppressor. Journal of Cellular Biochemistry, 1998, 72, 43-49.	1.2	10
113	The Chimeric E2A-HLF Transcription Factor Abrogates p53-Induced Apoptosis in Myeloid Leukemia Cells. Blood, 1998, 92, 1397-1405.	0.6	3
114	Mdm-2: â€œbig brotherâ€•of p53. , 1997, 64, 343-352.		149
115	Mdm-2: â€œbig brotherâ€•of p53. , 1997, 64, 343.		1
116	Gain of function mutations in p53. Nature Genetics, 1993, 4, 42-46.	9.4	837
117	Position and orientation-selective silencer in protein-coding sequences of the rat osteocalcin gene. Biochemistry, 1993, 32, 13636-13643.	1.2	35
118	A comparison of the biological activities of wildâ€type and mutant p53. FASEB Journal, 1993, 7, 855-865.	0.2	417
119	The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 1992, 69, 1237-1245.	13.5	2,890
120	Disruption of the cytoskeleton with cytochalasin D induces c-fos gene expression. Experimental Cell Research, 1991, 192, 93-101.	1.2	57
121	Differential association of membrane-bound and non-membrane-bound polysomes with the cytoskeleton. Experimental Cell Research, 1990, 191, 246-255.	1.2	50
122	Histone gene expression remains coupled to DNA synthesis during in vitro cellular senescence. Experimental Cell Research, 1987, 172, 397-403.	1.2	12
123	Subcellular localization of histone messenger RNAs on cytoskeleton-associated free polysomes in HeLa S3 cells. Journal of Cellular Physiology, 1985, 125, 345-353.	2.0	31
124	Evidence that the cro repressor inhibits expression of the bacteriophage Î»P gene at high multiplicities of infection. Molecular Genetics and Genomics, 1984, 193, 322-326.	2.4	1